This is a working overview of Stenabolic, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
If there is an increase in length of the material line, the normal strain is called tensile strain; otherwise, if there is reduction or compression in the length of the material line, it is called compressive strain.
The various temperature rests favour the activity of different enzymes, depending on the type and modification level of the malt and the brewer's intentions. Of particular importance are α-amylase and β-amylase, which hydrolyse starch to produce dextrins and fermentable sugars such as maltose. A traditional step mash may include a β-glucanase and protein rest around 45 °C (113 °F), a β-amylase rest around 62 °C (144 °F), and an α-amylase rest around 70 °C (158 °F). With modern well-modified malts, the lower-temperature rests are often omitted, and mashing may begin directly at temperatures where the amylases are more active. β-glucanases break down β-glucans in the mash, while proteolytic enzymes break down proteins into smaller peptides and amino acids. In modern brewing, commercial β-glucanase preparations may also be added to the mash. During saccharification, a mash rest of around 65–71 °C (149–160 °F) is commonly used. Lower temperatures within this range favour β-amylase activity and generally produce a more fermentable wort, while higher temperatures favour α-amylase activity and generally produce a less fermentable wort containing more dextrins. Mash temperature, duration and pH therefore influence the carbohydrate composition and fermentability of the resulting wort.
== Business units and subsidiaries == Medtronic has four main business units: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group. Medtronic develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders and diabetes.
== Predisposing factors == Aortic dissection is associated with hypertension (high blood pressure) and many connective tissue disorders. Vasculitis (inflammation of an artery) is rarely associated with aortic dissection. It can also be the result of chest trauma. About 72 to 80% of individuals who present with an aortic dissection have a previous history of hypertension. Use of stimulants such as cocaine and methamphetamine is also a modifiable risk factor for AD. It can also be caused by smoking. A bicuspid aortic valve (a type of congenital heart disease involving the aortic valve) is found in 7–14% of individuals who have an aortic dissection. These individuals are prone to dissection in the ascending aorta. The risk of dissection in individuals with bicuspid aortic valves is not associated with the degree of stenosis of the valve. Connective tissue disorders such as Marfan syndrome, Ehlers–Danlos syndrome, and Loeys–Dietz syndrome increase the risk of aortic dissection. Similarly, vasculitides such as Takayasu's arteritis, giant cell arteritis, polyarteritis nodosa, and Behçet's disease have been associated with a subsequent aortic dissection. Marfan syndrome is found in 5–9% of individuals who had an aortic dissection. In this subset, the incidence in young individuals is increased. Individuals with Marfan syndrome tend to have aneurysms of the aorta and are more prone to proximal dissections of the aorta. Turner syndrome also increases the risk of aortic dissection, by aortic root dilatation.
Sources: en.wikipedia.org
==== Africa ==== During Xi's administration, China has maintained cordial relationships with each Africa government except Eswatini, which recognizes Taiwan but not the PRC. Under Xi, China has cut back lending to Africa after fears that African countries could not repay their debts to China. Xi has also promised that China would write off debts of some African countries. In 2025, China announced that it would remove nearly all import tariffs on African countries.
"Tetrachlorodecaoxide" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties. WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection. Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie. The chemical formula is given as Cl4H2O114-. This incomplete formula shows a mixture of chlorite ion, water, and molecular oxygen: "Cl4H2O114-" = 4ClO2− + H2O + O2. Oxoferin was found to be equivalent with aqueous sodium chlorite. Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis, is effective in the treatment of diabetic foot ulcers, and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.
Additional regulation over the housing market would have been beneficial, according to former Federal Reserve chairman Alan Greenspan. Bush, meanwhile, proposed a financial rescue plan to buy back a large portion of the U.S. mortgage market. Vince Reinhardt, a former Federal Reserve economist now at the American Enterprise Institute, said "it would have helped for the Bush administration to empower the folks at Treasury and the Federal Reserve and the comptroller of the currency and the FDIC to look at these issues more closely", and additionally, that it would have helped "for Congress to have held hearings".
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.